Sun Pharma's Specialty Business Lifts Q1 Profit 27%, Revenue Climbs to Rs 15,300 Crore

That portfolio, commanding higher margins, includes treatments for ​skin disorders, cancer and other chronic diseases.

Specialty sales rose 12.8% ⁠to $351 million, accounting for 21.9% of total revenue. Growth was driven by ​a 16% rise in India, its biggest market, while U.S. sales were broadly ​flat.

"Sun's India business has been the major growth driver this quarter, with growth driven by new launches in the specialty segment," said Vishal Manchanda, a pharma analyst with ​Systematix Institutional Equities.

"Sun is one of the companies in India which is ​the first to bring a new product to the market and that gives them an ‌edge ⁠in setting the pricing as well," Manchanda said.

Sun has also been expanding overseas through acquisitions, including its planned $11.75 billion purchase of Organon , opens new tab, which would be the largest cross-border deal by an Indian drugmaker.

Consolidated net profit rose to ​28.95 billion rupees ($303.5 ​million) in the ⁠quarter ended June 30 from 22.79 billion rupees a year earlier, while revenue increased 10.5% to 153 billion rupees. ​Analysts had expected a profit of 29.90 billion rupees, ​according to ⁠LSEG data.

The company took a one-time charge of 2 billion rupees during the quarter related to the Organon acquisition.

Like its peers, Sun Pharma is also targeting ⁠India's ​fast-growing obesity and diabetes market with generic ​versions of semaglutide, the active ingredient in Novo Nordisk's , opens new tab blockbuster drugs Wegovy and Ozempic.

Also Read: Sun Pharma Partners Hypera Pharma to Launch Semaglutide in Brazil After ANVISA Nod